Kenneth Research recently added a report on ‘Peptide Based Infection Therapeutics Industry Market’ in its database of market research reports which provides its readers an in-depth analysis on the latest trends, growth opportunities and growth drivers that are associated with the growth of the market. The report additionally shares critical insights on the COVID-19 impacts on the Peptide Based Infection Therapeutics Industry Market, along with the compound growth rate (CAGR) of the market for a projected period between 2022 and 2031. The report also includes analysis of the market by utilizing different analytical tools, such as PESTEL analysis and Porter’s five forces analysis. These tools also provide an in-depth analysis on the micro and macro-environmental factors that are associated with the growth of the market during the forecast period.
In Q4 2021, U.S. current-account deficit widened stood at $224.8 billion. However, in Q1 22, CAD rose by 29.6%, reached to $291.4 billion, adding $66.6 billion to the gap. Export of good and services increased by $25.7 billion to reach $1.03 trillion in the first quarter of 2022. However, country’s goods and services deficit was $79.6 billion in June, down $5.3 billion from $84.9 billion in May, revised- reflecting some sight of relief. On the other hand, annual inflation rate in the country hit 8.5%. Energy CPI surged by 32.9% in July 2022, inflating the cost of logistic and signs to disrupt supply chain whilst electricity cost upsurged by 15.2%, highest since Feb 2006. Apart from that, In July 2022, existing US home sales declined 5.9% to 4.81 million (seasonally adjusted annual rate), the lowest since May of 2020 and below market expectations of 4.89 million. As mortgage rate touches highest at 6%, sales for houses declined for a sixth consecutive month. Global energy crises to remain at focal point impacting the economic activity in the U.S, pushing consumers to spend less on the products and services and save more.
On the other hand, the worst is expected to be seen in the European countries, especially during 2022 winters. The energy and gas crises has already started grappling the region, wherein many Western European countries including Germany is looking for coal fired solutions to tackle the gas supply shortage created by Russian-Ukraine conflict.
Amidst global concerns, market players have started looking for safe investments by holding on to the new technology and product launches. Factors like currency translation, disruption in global supply chain, Anti-China sentiments brewing across the globe, slowdown in Chinese economy, inflated products prices, USD getting stronger every week, decreasing purchasing power and strict measures taken by central banks/institutions across the world to ensure less spending and more saving, could hit the demand for the product and service badly in near future.
Healthcare Companies and Private Service Providers to have a minimal damage Caused by Inflation:
As US govt. remains committed to quality by spending more in the Medicaid and Medicare programs, incentives by govt. to medical devices, pharma companies and biotech to benefit the market players in short and long term goals. In 2021, U.S. spent $12,318/person on healthcare- highest amongst all OECD countries followed by Germany at $7,383. The federal government commitment towards healthcare systems to enable market players expanding their revenues and mitigating the risk posed by the inflation.
The request of this Sample Report here – https://www.kennethresearch.com/sample-request-10151792
“The global peptide based infection therapeutics market is estimated to be valued at more than ~USD 40 billion in 2021 and is expected to grow at a compound annual growth rate of 10% during the forecast period 2022-2030. The increasing prevalence of cancer and metabolic disorders (such as osteoporosis, obesity, and diabetes) are key factors in the use of peptide therapy during the prognosis period. Due to the increasing base of the affected paediatric population and the prevalence of targeted diseases in low-income countries, the demand for highly effective and low-cost drugs is very high. The growth is directly related to the increase in investment in drug discovery.
The research and development activities of peptide therapy mainly focus on the development of tumor drugs, followed by infectious diseases, metabolic disorders and diabetes. The existence of a strong product portfolio in this segment is also one of the factors that is expected to drive market growth soon.
In addition, advances in peptide manufacturing processes are expected to promote the development of future therapies. As many companies take measures to investigate the development of new drug candidates, the market is expected to show profitable growth during the forecast period. In order to maintain its market position, the company participates in extensive research and development activities to develop new drugs that show higher efficiency in treating target diseases.
Clinical trials of these drugs have also increased significantly in the past decade. This is also expected to drive growth during the forecast period. Manufacturers and suppliers are focusing on new technologies for peptide synthesis. Improvements in the purification process as well as automation and less waste generation are among the factors that promote growth. In addition, it is expected that during the forecast period, the increasing use of hybrid technologies for efficient drug manufacturing will increase production.
The cancer field dominated in 2020, generating more than USD 3 billion in revenue. The global increase in the prevalence of cancer and the increase in the prescription of peptide therapies for the treatment of cancer are the key factors leading to the dominance of this market segment. The increasing demand for highly effective and quick-acting therapies is expected to intensify the growth.
Increasing awareness among patients and healthcare professionals of the adverse effects of chemotherapy and radiotherapy is a high-yield factor in increasing attention to alternative therapies, such as peptide-based drugs. The above reasons are expected to promote cancer as the fastest growing application. In addition, the existence of a strong product portfolio is expected to confirm progress. The incidence of metabolic disorders is accelerating. A sedentary lifestyle, unhealthy eating habits and heavy drinking have led to an increase in the incidence of these diseases. In addition, it is estimated that the continuous growth of the elderly population susceptible to metabolic disorders will provide a potential growth platform for the market.
Drug type information:
Classify the market according to the types of generic drugs and innovative drugs. Innovative peptides dominated in 2020, with a share of approximately ~70%. This was due to the increasing R&D investment and high prescription rate of large pharmaceutical companies in the development of new drugs. Generic drugs achieved lucrative growth during the forecast period.
It is expected that the federal government’s increased health care expenditures and health care expenditures will promote the adoption of generic drugs. The estimated loss of patents for many branded drugs is also a key factor leading to the growth of the generic drug market. The loss of patents is seen as an excellent opportunity for generic drug companies to enter the market with low-cost alternatives to replace very successful drugs. However, in the case of certain innovative drugs, brand loyalty will affect the growth of this market segment. The incidence of metabolic disorders is accelerating. A sedentary lifestyle, unhealthy eating habits and heavy drinking have led to an increase in the incidence of these diseases. In addition, it is estimated that the continuous growth of the elderly population susceptible to metabolic disorders will provide a potential growth platform for the market.
Manufacturing type information:
The internal manufacturing sector accounts for the largest proportion, accounting for more than 65% in 2020. Due to strict supervision and high cost, most of the main players participate in the outsourcing of internal development of peptide therapy. Because large pharmaceutical companies have infrastructure suitable for mass production and advanced technology, these companies prefer in-house manufacturing.
As it is difficult to manufacture therapeutic products in accordance with high-quality standards, it is expected that manufacturing outsourcing activities will also increase during the forecast period. Companies prefer to outsource Active Pharmaceutical Ingredients (API) to companies with the most advanced technology and experience to manufacture various types of peptides.
The manufacture of peptides is a complex process that requires advanced technologies, such as solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS) or Hybrid for purification and synthesis of high-quality products, resulting in high manufacturing costs. In addition, it is expected that major players will sign strategic agreements to increase R&D funds and equity investment, which will lead to market growth during the forecast period.
Information on the route of administration:
Biopharmaceutical giants are constantly exploring new peptide-related drug delivery methods. The efficacy of new drug delivery technologies with advanced PEGylated engineered molecules is currently being evaluated, in an attempt to improve drug delivery performance and patient compliance through better drug delivery modes. However, inhibition of the enzymatic degradation of blood absorption of these drugs has great disadvantages. In 2020, injections were the mainstay, which accounted for a relatively large proportion.
This advantage is mainly due to the high adoption rate, faster drug delivery and ease of application. Due to the physiological characteristics of the respiratory system, the pulmonary route is thought to be used for the administration of peptides and proteins. Several proteins and peptides are currently in clinical trials, awaiting approval for use in the lungs.
However, low bioavailability and low molecular weight molecules that pass through the alveolar epithelium and cause inflammation are the main obstacles to use; however, other approaches, such as intradermal injection and intranasal injection, are expected to be richer than 13% during the forecast period. Compound annual growth rate growth. The bioavailability of the nasal route was found to be greater than 3%, which makes it superior to the oral route. In addition, transdermal and transnasal prevent enzymatic degradation of peptides.
Due to the growing demand for pure peptides for the development of high-efficiency therapies, the LPPS market segment dominated in 2020 with a share of more than 43%. However, issues such as increased time consumption have led consumers to switch to faster and more effective methods such as SPPS. SPPS reduces synthesis time and is used in a wide range of production procedures.
In addition, higher efficiency in the synthesis of longer peptides is another market driver. In addition, related automation, scalability, and improved control over the physical and chemical properties of peptides are expected to drive the market during the forecast period. Due to related benefits, hybrid technologies are expected to lead the growth, such as compatible synthesis with liquid phase synthesis and solid synthesis. Phase synthesis. The company is investing in research and development to integrate the advantages of LPSS and SPSS and provide cost-effective and sustainable solutions. Due to the high adoption rate, advanced hybrid technology is expected to grow at a robust compound annual growth rate of over 11%.
Major players in this industry include Eli Lilly; Pfizer; Amgen; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industry Co., Ltd.; Lonza; Sanofi; Bristol-Myers Squibb (BMS); Silicon; GlaxoSmithKline (GSK); Novartis; and Novo Nordisk A/S. The development of new products and the implementation of technological advancements are key strategies for the company to gain market position. In addition, it is estimated that increased cooperation to test new drugs will increase competition. For example, Cancer Research UK has reached an agreement with Bicycle Therapeutics to fund phase Ia and Ib clinical trials of the drug candidate BT1718 for the treatment of solid tumors.
Market segments covered by the report:
The report forecasts global, regional and national revenue growth, and analyzes the latest trends and opportunities in each sub-segment from 2022-2030. In this study, Kenneth Research segmented the peptide therapy market by application, type, manufacturer type, route of administration, synthesis technology, and region: application prospects (revenue, millions of dollars; 2022-2030) metabolic disorders Cardiovascular Respiratory GIT Anti-infective Pain Skin Disease CNS Kidney Other Types Outlook (Revenue, USD) Million; 2014-2025) GenericInnovativeType of Manufacturer Outlook (Revenue, Million USD; 2022-2030) Internal Outsourcing Drug Delivery Route Outlook (Revenue, Millions of dollars; 2022-2030) Parenteral route, oral route, and other synthetic technologies of lung mucosa (revenue, revenue) million; 2022-2030) Solid-phase peptide synthesis (SPPS)) Technology mixed liquid-phase peptide synthesis (LPPS). ”
Read more Reports@
Japan Herpes Zoster Oticus Market
Japan Hepatitis C Virus (HCV) Market
Japan Vestibular Schwannoma Market
Japan Chronic Refractory Gout Market
Japan REM Sleep Behavior Disorder Market
Japan Immunologic Deficiency Syndrome Market
Kenneth Research provides scheduled syndicated reports that help industry professionals and organizations decipher market trends to take significant decisions and plan strategies. We cater to a wide range of industries including healthcare & pharmaceuticals, ICT & telecom, automotive & transportation, energy & power, chemicals, FMCG & food, aerospace & defense, among others. Our research team ensures to track and analyze the industry on a regular basis to offer strategic business consultancy services on a global level. We, at Kenneth Research are adept at capturing descriptive insights on crucial topics to help our clients make their informed decisions.
Name: Kenneth research
Phone: +1 313 462 0609